Abstract
dc:descriptionThe Gonadotropin-Releasing Hormone (GnRH) (or LHRH: luteinizing hormone-releasing hormone) is a decapeptide, which is produced and released in pulses from the hypothalamus, controlling the release of the gonadotropin hormones LH (luteinizing hormone) and FSH (follicle-stimulating hormone) from the anterior pituitary gland. The actions of GnRH are mediated through its interaction with GnRH receptors (GnRH-R). The GnRH-R are G protein-coupled receptors (GPCRs) located in the plasma membrane of cells. In addition to the pituitary gland, GnRH receptors are also highly expressed in various cancers, including cancers of the ovary and endometrium. The biological effects resulting from the interaction of GnRH and related analogues with the GnRH-R are mainly due to the activation of different G proteins, such as Gαq and Gαi. The expression of GnRH receptors in hormone-dependent cancers is the basis for the therapeutic treatment of these cancers, using drugs that specifically target the GnRH-R. Recently, research groups developed a targeted anticancer approach to treat GnRH-expressing tumors, using the complex D-Lys6-LHRH-doxorubicin (zoptarelin-doxorubicin). Following the interaction of zoptarelin-doxorubicin with GnRH receptors on cancer cells and the subsequent internalization of the receptor-ligand complexes, doxorubicin is released intracellularly and exerts its cytotoxic effects. However, doxorubicin has side effects, including cardiotoxicity. Although the zoptarelin-doxorubicin complex showed promising results in Phase I and Phase II clinical trials, it did not demonstrate a statistically significant improvement in overall survival in Phase III clinical trials, nor did it improve the safety profile compared to doxorubicin alone. Moreover, this conjugate can be hydrolyzed by plasma carboxylesterases, releasing the cytotoxic agent before it reaches the target cancer cell. The above disadvantages of the zoptarelin-doxorubicin conjugate led us, in collaboration with Dr. Tselios (Dept of Chemistry, Univ. of Patras), to design and synthesize two novel conjugates, named con3 and con7, which are GnRH analogues linked through a disulfide bond to the anticancer agent mitoxantrone. Mitoxantrone has fewer side effects than doxorubicin. Furthermore, the disulfide bond linking the GnRH analogue and mitoxantrone in con3 and con7 is not vulnerable to plasma esterases, in contrast to the ester bond of the zoptarelin-doxorubicin conjugate. Con3 and con7 release mitoxantrone by exploiting the thioredoxin system, which is overexpressed in cancer cells and reduces disulfide bonds. In the present study, we pharmacologically characterized the con3 and con7 conjugates, using the GnRH-R-expressing ovarian SKOV3 and endometrial Ishikawa cancer cells. We demonstrated that con3 and con7 bind strongly to the GnRH-R and are GnRH agonists, as they activate the Gαq signaling pathway. These analogues reduced the proliferation rate of SKOV3 and Ishikawa cancer cells and induced apoptosis in vitro. Upon binding of con3 and con7 to GnRH-Rs on cancer cells, the conjugated mitoxantrone was released from them using the extracellular thioredoxin system of cancer cells which cleaved the disulfide bond linking the anticancer drug with the GnRH analogues. Subsequently, the released lipophilic mitoxantrone passively entered the cancer cells, where it exerted its anticancer effects.These findings highlight the importance of the GnRH/GnRH-R system in the development and progression of ovarian and endometrial cancer cells and its exploitation to develop new targeted therapies against these types of cancer.
Degree
thesis:*- Grantor dc:publisher
- University of Crete (UOC)
- Year dc:date
- 2026
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Markatos, Christos-Georgios
- Μαρκάτος, Χρήστος-Γεώργιος
Subjects
dc:subject × 13Rights
- Language dc:language
- eng
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/62984